Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 254-104-8 | CAS number: 38725-13-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 12 March 2018 to 18 May 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- Adopted 22 July 2010
- Deviations:
- no
- GLP compliance:
- yes
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Reference substance name:
- Triisononylamine
- EC Number:
- 254-104-8
- EC Name:
- Triisononylamine
- Cas Number:
- 38725-13-2
- Molecular formula:
- C27H57N
- IUPAC Name:
- tris(7-methyloctyl)amine
- Test material form:
- liquid
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material:
batch no. 99671, supplied by the sponsor
- Expiration date of the lot/batch: 9 October 2019
- Purity test date:6 November 2017
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Room temperature 20±5°C
- Stability under test conditions: Stable
- Solubility and stability of the test substance in the solvent/vehicle: The vehicle was selected according to current OECD TG 429, the test item was soluble in the vehicle, therefor a homogeneous solution was obtained
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: not applicable
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: The required amount of the test item (according to the concentration) was mixed with the vehicle shortly before the administration . The preparations were made freshly before each dosing occasion
- Preliminary purification step (if any): not applicable
- Final dilution of a dissolved solid, stock liquid or gel: 50% concentration was obtained by mixing of 0.5 mL of test item with 0.5 mL of vehicle
- Final preparation of a solid: the test item was mixed with the vehicle
FORM AS APPLIED IN THE TEST (if different from that of starting material)
in solution in the vehicle
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- CBA/Ca
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Velaz, Prague, Czech Republic
- Females (if applicable) nulliparous and non-pregnant: yes
- Microbiological status of animals, when known: The health condition of animals was examined by a veterinarian before initiation of the study, no more details
- Age at study initiation: 8-11 weeks
- Weight at study initiation: 19.64±0.911g
- Housing: The animals were housed in IVC polycarbonate cages (5 animals per cage) suspended on stainless steel racks, in a room equipped with central air-conditioning.
- Diet (e.g. ad libitum): A laboratory food ssniff was served ad libitum, each day approximately at the same time.
- Water (e.g. ad libitum): The animals received tap water for human consumption. Supply of drinking water was unlimited
- Acclimation period: 5 days
- Indication of any skin lesions: no indication of lesion
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±3°C
- Humidity (%): 50-60% Relative Humidity
- Air changes (per hr): centrail air conditionning, no more details
- Photoperiod (hrs dark / hrs light): 12 hours / 12 hours
- IN-LIFE DATES: From: 15 March 2017 To: 17 April 2018
Study design: in vivo (LLNA)
- Vehicle:
- acetone/olive oil (4:1 v/v)
- Concentration:
- Pre screen test : 100%
Main test : 50, 25, 10% - No. of animals per dose:
- Pre test : 2 animals were used
Main test : 5 animals were used per condition - Details on study design:
- PRE-SCREEN TESTS:
- Compound solubility: the compound is soluble in the vehicle
- Irritation: local irritation was evaluated
- Systemic toxicity: signs of systemic toxicity were evaluated
- Ear thickness measurements: performed
- Erythema scores: performed
The pre-screen test was conducted under the same conditions as the main LLNA study, except the assessment of lymph node proliferation. The undiluted test item was considered as 100% concentration.
Test procedure of Pre-screen test
All mice (2 mice/group) were observed daily for any clinical signs of toxicity or local irritation at the application site. Body weights were recorded pre-test and prior to the termination (day 6). Both ears of each mouse were assessed for any signs of irritation. Ear thickness was measured by a calliper on Day 1 (pre-dose), Day 3 and Day 6. Excessive local skin irritation is indicated by an erythema score ≥ 3 and/or an increase in ear thickness of ≥25%.
MAIN STUDY
Schedule :
Day 1: Each animal was identified and the body weight was recorded. To the dorsum of each ear 25µL of the appropriate dilution of the test item, or the vehicle alone was applied.
Days 2 and 3: The application procedure carried out on day 1 was repeated.
Days 4 and 5: No treatment.
Day 6: The body weight of each animal was recorded. 250µL of phosphate-buffered saline (PBS) containing 2 µCi (7.4 x 10E4 Bq) of 125I-iododeoxyuridine and 10-5M fluorodeoxyuridine was injected into all test and control mice via the tail vein.
Animals were carefully observed for any clinical symptoms, either of local irritation at the application site or systemic toxicity. The daily clinical observation of the animals did not show visible clinical signs. The animal body weights were measured prior to the first treatment and at the scheduled sacrifice
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: LLNA
- Criteria used to consider a positive response:
Results are expressed as the Stimulation Index (SI). The SI was obtained by dividing the pooled DPM for each treatment group by the incorporation of the pooled DPM vehicle control group; this yields a mean SI. A substance is regarded as sensitizer in the LLNA test when SI≥3.
EC3 value, which induce stimulation indices, is determined by linear interpolation of points on dose-response curve, immediately above and below of SI value, according to the equation: EC3=c+[(3-d)/(b-d)]x(a-c)
a – higher concentration, b – SI of higher concentration, c – lower concentration
d – SI of lower concentration
If all points are below the stimulation index of three, no EC3 value can be stated.
When there are no data points that fall below SI = 3, log-linear extrapolation may be applied in which the two lowest test concentrations from the dose-response curve are used, provided the lowest SI value approaches the value of 3 and that a linear dose-response exists. The equation for EC3 calculation:
EC3 =2^{log2(c)+ (3−d)/(b−d)×[log2(a)−log2(c)]}
a – concentration for next lowest SI above 3, b – next to lowest SI above 3,
c – concentration for lowest SI above 3, d – lowest SI above 3
TREATMENT PREPARATION AND ADMINISTRATION:
The required amount of the test item (according to the concentration) was mixed with the vehicle shortly before the administration (i.e. 50% concentration was obtained by mixing of 0.5 mL of test item with 0.5 mL of vehicle). 25 µL of the test item was applied to the dorsum of each ear. The alpha-Hexyl cinnamaldehyde (25%) as positive control and vehicle as a negative control were administrated in the same volume. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
Results and discussion
- Positive control results:
- The positive control induced a SI value calculated at 6.22.
In vivo (LLNA)
Resultsopen allclose all
- Key result
- Parameter:
- SI
- Value:
- 6.22
- Test group / Remarks:
- Positive Control
- Key result
- Parameter:
- SI
- Value:
- 7.38
- Test group / Remarks:
- Triisononylamine 10%
- Key result
- Parameter:
- SI
- Value:
- 12.82
- Test group / Remarks:
- Triisononylamine 25%
- Key result
- Parameter:
- SI
- Value:
- 13.47
- Test group / Remarks:
- Triisononylamine 50%
- Key result
- Parameter:
- EC3
- Value:
- 4.78
- Test group / Remarks:
- Triisononylamine
- Cellular proliferation data / Observations:
- PRE SCREEN TEST
Triisononylamine administered at concentration of 100%, caused in both mice apathy observed on days 1 and 2; animals did not react on touch and had weak intake of food and water. Third day after application due to strong signs of toxicity, animals were humanely killed. Effect on erythema score and ear thickness was not observed.
Triisononylamine administered at concentration of 50%, did not caused any changes in monitored parameters
CELLULAR PROLIFERATION DATA
In comparison with the control group, an increase of the pooled lymph node weights at all concentrations was observed. The increase was strong and dose dependent. The pooled lymph node weights of treated groups were 0.1157g for 10% concentration, 0.1236g for 25% concentration and 0.1335g for 50% concentration of tested item. The lymph node weight of control group and positive control group were 0.0314g and 0.0778g, respectively.
DETAILS ON STIMULATION INDEX CALCULATION
The DPM values for the three treated groups were 11215 (10%), 19493 (25%) and 20478 (50%), respectively. The SI values for the three treated groups were 7.38 (10%), 12.82 (25%) and 13.47 (50%), respectively
EC3 CALCULATION
The EC3 calculation was detailed in section "details on the study design"
CLINICAL OBSERVATIONS:
The daily clinical observation of the animals did not show visible clinical signs.
BODY WEIGHTS
The minor increase of body weight was observed at all used concentrations, without statistical significance.
Any other information on results incl. tables
Table 1. Clinical Observations for thePre screentest with test item at 100%
Signs/Day |
Day 1 |
Day 2 |
Day 3 |
Day 4 |
Day 5 |
Day 6 |
||||||
Mouse 1 |
Mouse 2 |
Mouse 1 |
Mouse 2 |
Mouse 1 |
Mouse 2 |
Mouse 1 |
Mouse 2 |
Mouse 1 |
Mouse 2 |
Mouse 1 |
Mouse 2 |
|
Apathy |
+ |
0 |
++ |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
Ataxia |
- |
0 |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
Intake of food |
Weak |
Weak |
Weak |
Weak |
- |
- |
- |
- |
- |
- |
- |
- |
Intake of water |
Weak |
Weak |
Weak |
Weak |
- |
- |
- |
- |
- |
- |
- |
- |
Tremor |
0 |
0 |
0 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
Change in grooming activity |
0 |
0 |
0 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
Pilo-erection |
0 |
0 |
0 |
0 |
- |
- |
- |
- |
- |
- |
- |
- |
- notanalysed 0 no effect + weak effect ++ moderate effect +++ strong effect
Table 2.Erythema score for thePre screentest with test item at 50%
Mouse no. |
Day 1 |
Day 2 |
Day 3 |
Day 4 |
Day 5 |
Day 6 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
Table 3.The Lymph node weight, DPM, SI, EC3 values for the main test
|
Lymph node |
Number of |
|
|
|
|
weight (g) |
lymph nodes |
DPM |
SI |
EC3 (%) |
Control |
0.0314 |
10 |
1520 |
- |
4.78 |
Positive Control |
0.0778 |
10 |
7210 |
6.22* |
|
Triisononylamine10% |
0.1157 |
10 |
11215 |
7.38 |
|
Triisononylamine25% |
0.1236 |
10 |
19493 |
12.82 |
|
Triisononylamine50% |
0.1335 |
10 |
20478 |
13.47 |
Applicant's summary and conclusion
- Interpretation of results:
- Category 1B (indication of skin sensitising potential) based on GHS criteria
- Conclusions:
- Under the experimental condition of the study, the test substance triisononylamine induced an EC3 value of 4.78% on the LLNA. Hence, according to CLP criteria, the triisononylamine was classified as sensitizer category 1B.
- Executive summary:
The skin sensitization potential of Triisononylamine was evaluated by LLNA method, under GLP compliance and according to OECD TG 429 method.
The test item was suspended in Acetone:Olive Oil 4:1 (v/v). The positive control (Alpha-Hexylcinnamic aldehyde) (25%) was dissolved in the same vehicle.
The Pre-screen test was performed using a dose of 100 % and 50%. Based on the observations recorded in the Pre-screen tests, the concentration of 50 % was selected as top dose for the main test.
In the present study, the test item was applied to the dorsum of each ear of five female mice (CBA/Ca) per group over three consecutive days, at three concentrations.
All animals survived throughout the test period without showing any clinical signs. In comparison with the control group, the strong increase in lymph node weight was observed at all used concentrations. The increase of lymph node weight was dose dependent. A similar trend was registered in the evaluation of DPM of the lymph nodes. Calculated SI values in treated groups were higher than 3 at the all used concentrations. The calculated EC3 value is 4.78%. As the SI for some treatment dose group is ≥3 and a clear dose response relationship is observed, the test item is regarded as a potential skin sensitizer.
These results demonstrate that the test item Triisononylamine was a skin sensitizer under the test conditions of this study.
Under the experimental condition of the study, the test substance triisononylamine induced an EC3 value of 4.78% on the LLNA. Hence, according to CLP criteria, the triisononylamine was classified as sensitizer category 1B.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.